Medline (MDLN)

Medline sells a large catalogue of proprietary products under the Medline brand, spanning areas such as front-line patient care, surgical products, infection prevention, laboratory and diagnostics, and other everyday clinical consumables. It also distributes third-party items sourced from a wide vendor base, giving healthcare providers a single channel for both branded and externally manufactured products. This breadth is important in a sector where reliability, availability, and cost control are central to hospital operations.

The company’s scale is one of its defining features. Medline operates an extensive manufacturing and distribution footprint, supported by more than 30 manufacturing facilities and a large owned truck fleet that enables direct delivery to customers. Most of its revenue comes from the United States, where it works with some of the country’s largest health systems and benefits from deep relationships in the medical-surgical supply market.

Medline became a public company in December 2025, giving investors exposure to a business tied to recurring healthcare demand, hospital procurement, and the ongoing need for efficient medical supply chains. Its performance is influenced by healthcare utilization, contract wins and renewals, product sourcing costs, and the company’s ability to maintain service levels across a complex national distribution network.